Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01233635 · ClinicalTrials.gov registry record · Phase 4
Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)
A Phase 4 study, sponsored by University of Pittsburgh.
- Terminated
- Registry status
- Phase 4
- Development phase
- 228
- Enrollment target
NCT01233635: Clinical Trial Phase 4 study, sponsored by University of Pittsburgh.
NCT01233635 is a Phase 4 study that was terminated before completion, run by University of Pittsburgh. The registered enrollment target is 228 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01233635, a Phase 4 study, was terminated before completion, sponsored by University of Pittsburgh.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 228 participants
- Enrollment target
Study Summary
In the present application, we propose to refine and extend current insight into AAF mechanism and therapy by examining the importance of pharmacologic RAAS inhibition, ACE genotype, and their interaction in secondary AF prevention. We have 3 specific aims: 1. To confirm that RAAS inhibition therapy reduces the incidence of AF recurrence. 2. To test the hypothesis that the incidence of AF recurrence in the absence of RAAS inhibition therapy is higher among patients with the D allele. 3. To explore the hypothesis that RAAS inhibition therapy is more effective for preventing AF recurrence in patients with the DD genotype than in those with DI or II genotypes.
Interventions
- OTHER no drug
- DRUG start cozaar
- DRUG continue cozaar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
Why NCT01233635 stopped before completion
NCT01233635 is an interventional study that assigns participants to a tested intervention. The registered 228 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 3 interventions - of which no drug is the first listed.
NCT01233635 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01233635 about?
NCT01233635 is a clinical study titled "Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)". In the present application, we propose to refine and extend current insight into AAF mechanism and therapy by examining the importance of pharmacologic RAAS inhibition, ACE genotype, and their interaction in secondary AF prevention. We have 3 specific aims: 1. To confirm that RAAS inhibition therap...
What is the current status of trial NCT01233635?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 228 participants. The study started on 2005-11. Estimated completion is 2007-11.
What interventions are being tested in trial NCT01233635?
The interventions under investigation include: no drug (OTHER), start cozaar (DRUG), continue cozaar (DRUG).
Who is sponsoring clinical trial NCT01233635?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01233635's enrollment target sits among peer trials
228 374th of 2000 higher than 1,625 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
- NCT05547698 · 228 participants · NA
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
- NCT05630963 · 228 participants
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
- NCT06073665 · 228 participants · Phase 4
Dosing of LT4 in Older Individuals
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia